Press Releases

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
Maverick Therapeutics Announces Key Executive Promotion and Scientific Advisory Board Appointments to Further Prepare for Clinical Development in 2021
Maverick Therapeutics Reveals Preclinical Data from COBRA™ Program, MVC-280, at Virtual Cell Engager Summit 2020
Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA™ Platform
Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA™ Platform at the Jefferies Virtual Global Healthcare Conference
Maverick Therapeutics to Participate at 2020 Jefferies Virtual Healthcare Conference
Maverick Therapeutics Appoints Dr. Chulani Karunatilake as Senior Vice President of Technical Operations
Maverick Therapeutics To Unveil Pre-clinical Data On Novel COBRA™ Platform At American Association For Cancer Research 2019 Annual Meeting
Maverick Therapeutics Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline of Next Generation T Cell Therapeutics in Immuno-Oncology
Maverick Therapeutics Advances Technology; Adds Key Management
Maverick Therapeutics Appoints James S. Scibetta as CEO
Maverick Therapeutics and Takeda Announce Five-year Exclusive Collaboration to Advance T-Cell Engagement Therapies